Merck Gets FDA Priority Review of Welireg
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.
In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Merck expands operations to position itself as a critical manufacturing hub in the APAC region: Our Bureau, Bengaluru Monday, January 27, 2025, 10:45 Hrs [IST] Merck has announced ...
Visitors can capture their photos with the Red Card at the stand to contribute to a powerful visual Mosaic symbol of ...
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.
Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...
These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback